Common genetic variants in prostate cancer risk prediction - Results from the NCI breast and prostate cancer cohort consortium (BPC3)

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 3, 2012, Pages 437-444

  Lindström, Sara ^a,b   Schumacher, Fredrick R ^e   Cox, David ^f,h   Travis, Ruth C ⁱ   Albanes, Demetrius ^j   Allen, Naomi E ⁱ   Andriole, Gerald ^k   Berndt, Sonja I ^j   Boeing, Heiner ^l   Bueno de Mesquita, H Bas ^m,n   Crawford, E David ^o   Diver, W Ryan ^p   Gaziano, J Michael ^c,d   Giles, Graham G ^q,r   Giovannucci, Edward ^b,c   Gonzalez, Carlos A ^s   Henderson, Brian ^e   Hunter, David J ^a,b,c   Johansson, Mattias ^g,t   Kolonel, Laurence N ^u   Ma, Jing ^c   Marchand, Loïc Le ^u   Pala, Valeria ^v   Stampfer, Meir ^b,c   Stram, Daniel O ^e   Thun, Michael J ^p   Tjonneland, Anne ^w   Trichopoulos, Dimitrios ^b,x   Virtamo, Jarmo ^y   Weinstein, Stephanie J ^j   Willett, Walter C ^b   Yeager, Meredith ^j   Hayes, Richard B ^z   Severi, Gianluca ^q   Haiman, Christopher A ^e   Chanock, Stephen J ^j   Kraft, Peter ^a,b   more..

^a Program in Molecular and Genetic Epidemiology   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CENTRE LÉON BÉRARD   (France)

^g INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j NATIONAL CANCER INSTITUTE   (United States)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^m NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o UNIVERSITY OF COLORADO   (United States)

^p AMERICAN CANCER SOCIETY   (United States)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r MONASH UNIVERSITY   (Australia)

^s CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^t UMEÅ UNIVERSITY   (Sweden)

^u UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^v NATIONAL CANCER INSTITUTE   (Italy)

^w INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^x BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^y NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^z NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MODEL; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; DISCRIMINANT ANALYSIS; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NATIONAL CANCER INSTITUTE (U.S.); POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84859386051     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-1038     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-803. (Pubitemid 351930854)
3. Bratt O. What should a urologist know about hereditary predisposition to prostate cancer? BJU Int 2007;99:743-7; discussion 747-8.
4. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011;104:1656-63.
5. Johansson M, Holmstrom B, Hinchliffe SR, Bergh A, Stenman UH, Hallmans G, et al. Combining 33 genetic variants with prostate specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer 2012;130:129-37.
6. Sun J, Kader AK, Hsu FC, Kim ST, Zhu Y, Turner AR, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 2011;71:421-30.
7. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5:977-85.
8. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
9. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:500-11. (Pubitemid 34081382)
10. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24. (Pubitemid 36313608)
11. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003; 12:84-9. (Pubitemid 36193996)
12. Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1137-41.
13. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004;4: 519-27. (Pubitemid 38868621)
14. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106. (Pubitemid 34830730)
15. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21(6 Suppl):349S-55S.
16. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, et al. Characterizing Associations and SNP-Environment Interactions for GWAS- Identified Prostate Cancer Risk Markers-Results from BPC3. PLoS One 2011;6:e17142.
17. Little RJA, Rubin DB. Single imputation methods. In:Little RJA, Rubin DB, editors. Statistical analysis with missing data. Hoboken, NJ: Wiley & Sons; 2002. p. 59-75.
18. Newson R. Confidence intervals for rank statistics: Somers' D and extensions. Stata J 2006:309-34.
19. SEER-13. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER
20. Regs Research Data, Nov 2009 Sub (1992-2007). [updated 2011 Nov 10; cited 2010 Oct 29]. Available from: http://seer.cancer.gov/.
21. Arias E. United States life tables, 2007. National vital statistics reports. vol 59 no 9. Hyattsville, MD: National Center for Health Statistics; 2011. Available from: http://www.cdc.gov/nchs/.
22. Dupont WD. Converting relative risks to absolute risks: a graphical approach. Stat Med 1989;8:641-51. (Pubitemid 19179865)
23. R Development Core Team (2009). R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009.
24. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21. (Pubitemid 351311772)
25. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72; discussion 207-12.
26. Gail MH. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J Natl Cancer Inst 2009;101:959-63.
27. Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 2011;30:1090-104.
28. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17.
29. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011;123: 551-65.
30. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882-90. (Pubitemid 38657490)
31. Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet 2010;6:e1000864.
32. Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsywith prostate-specific antigen alone: a systematic review. Eur Urol 2008;54:274-90.
33. Vickers AJ, Lilja H. Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol 2009;6:301-3.
34. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
35. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M, et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol 2011;60:21-8.
36. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010; 2:62ra92.